Search results
Results from the WOW.Com Content Network
Peripheral neuropathy, neutropenia, thrombocytopenia, anaemia, orthostatic hypotension, hepatitis (uncommon/rare), haemorrhage (uncommon/rare), heart failure (uncommon/rare), seizures (uncommon/rare), progressive multifocal leucoencephalopathy (PML) and hearing loss. Dactinomycin: IV: Complexes with DNA interfering with DNA-dependent RNA synthesis
Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. [18] It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia (in children and adults, but not recommended in elderly patients), rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura ...
Rituxan (rituximab) is a type of antibody therapy (biologic) medication that may be used with or without chemotherapy. It destroys or helps your body destroy blood cells that contain cancer.
Rituximab: 375 mg/m 2: IV infusion: Day 1 Etoposide: 50 mg/m 2: IV continuous infusion over 24 h: Days 1–4 Prednisolone: 60 mg/m 2: By mouth, twice a day (PO BID) Days 1–5 Oncovin: vincristine: 0.4 mg/m 2: IV continuous infusion over 24 h: Days 1–4 Cyclophosphamide: 750 mg/m 2: IV bolus given over 15 min: Day 5 Hydroxydaunorubicin ...
Rituximab: MabThera, Rituxan: mab: chimeric: CD20: Y [109] lymphomas, leukemias, some autoimmune disorders Rivabazumab pegol [12] mab: humanized: Pseudomonas aeruginosa type III secretion system: Robatumumab: mab: human: IGF-1 receptor (CD221) cancer Rmab: RabiShield: human: rabies virus G glycoprotein: Y: post-exposure prophylaxis of rabies ...
[3] [4] It is given by injection into a vein. [3] Common side effects include low blood cell counts, fever, nausea, diarrhea, loss of appetite, cough, and rash. [3] Other severe side effects include allergic reactions and increased risk of infection. [3] Use in pregnancy is known to harm the baby. [3]
Participants in the VEN+R arm completed a 5-week ramp-up venetoclax schedule and then received venetoclax 400 mg once daily for 24 months measured from the rituximab start date. [17] Rituximab was initiated after venetoclax ramp-up and given for 6 cycles (375 mg/m2 intravenously on cycle 1 day 1 and 500 mg/m2 intravenously on day 1 of cycles 2 ...
Hyper-CVAD chemotherapy consists of two combinations of drugs (courses A and B) given in an alternating fashion. The term 'hyper' refers to the hyperfractionated nature of the chemotherapy, which is given in smaller doses, more frequently, to minimize side effects.